These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35857415)

  • 1. Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    Bhatt A; Bhandoria G; Kepenekian V; Bakrin N; Glehen O
    Int J Cancer; 2022 Dec; 151(11):2055-2056. PubMed ID: 35857415
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    Koole SN; Schouten PC; van Driel WJ; Sonke GS; Linn SC
    Int J Cancer; 2022 Dec; 151(11):2057-2058. PubMed ID: 35857410
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
    Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
    Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
    Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Schwameis R; Chiva L; Harter P
    Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer].
    Schmalfeldt B
    Chirurgie (Heidelb); 2022 Dec; 93(12):1144-1151. PubMed ID: 36201013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
    Wang JY; Gross M; Urban RR; Jorge S
    Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
    Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer.
    Gajarawala S; Pelkowski J; Dorian R; Stanton A; Dinh T
    JAAPA; 2021 Aug; 34(8):50-53. PubMed ID: 34320542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
    Kim JH; Chun SY; Lee DE; Woo YH; Chang SJ; Park SY; Chang YJ; Lim MC
    Gynecol Oncol; 2023 Mar; 170():19-24. PubMed ID: 36608383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications.
    Pareja R
    Int J Gynecol Cancer; 2023 May; 33(5):841-842. PubMed ID: 36963802
    [No Abstract]   [Full Text] [Related]  

  • 17. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
    Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
    J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
    Alter R; Turaga K; Lengyel E
    JAMA Netw Open; 2020 Aug; 3(8):e2014184. PubMed ID: 32840618
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
    Wethington SL; Armstrong DK; Johnston FM
    JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.